Imatinib mesylate (CAS: 220127-57-1)
|
SKU-Pack Size | Availability | Size | Price | |
EBC51116-1ML | In Stock | 1mL(10mM in DMSO) | €50.70 | |
EBC51116-100MG | In Stock | 100mg | €50.70 | |
EBC51116-250MG | In Stock | 250mg | €76.70 | |
EBC51116-1G | In Stock | 1g | €180.70 |
Please Select The Country You Are In To Find Your Local Distributor. |
Cambiotech | Phone£º+44 (0) 188 448801 | |
Lanwades Business Park, | E-mail£ºinfo@cambiotech.com | |
Ireland | Kobenhavn K, Ireland | Web£ºwww.cambiotech.com |
Product Information | |||||||||||||||||||||
Synonym(s) | Gleevec, STI571, STI-571 | ||||||||||||||||||||
Chemical Name | 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide mesylate | ||||||||||||||||||||
Application | Imatinib mesylate is a c-Abl, PDGFR, and c-kit inhibitor that halts chronic myelogenous leukemia related growth | ||||||||||||||||||||
CAS Number | 220127-57-1 | ||||||||||||||||||||
Purity | ¡Ý99.0% | ||||||||||||||||||||
Molecular Weight | 589.73 | ||||||||||||||||||||
Molecular Formula | C₃₀H₃₅N₇O₄S | ||||||||||||||||||||
SMILES | CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O | ||||||||||||||||||||
Target & IC50 | PDGFR: IC50 = 0.1 ¦ÌM c-Kit: IC50 = 0.1 ¦ÌM K562 cells : IC50 = 0.21 ¦ÌM v-Abl: IC50 = 0.6 ¦ÌM |
||||||||||||||||||||
Solubility | DMSO: 59 mg/mL (100 mM)
H2O: 59 mg/mL (100 mM) |
||||||||||||||||||||
Preparing Stock Solutions |
|
||||||||||||||||||||
Shipping | Gel Pack | ||||||||||||||||||||
Storage | Store at -20¡ãC | ||||||||||||||||||||
Research Use | For Research Use Only. Not Intended for Diagnostic Or Therapeutic Use. |
Product Description | |
Imatinib mesylate is a small molecule that inhibits the c-Abl protein-tyrosine kinase, a kinase specifically important for proliferation of chronic myelogenous leukemia (CML). A translocation event between chromosomes 9 and 22 generates the Philadelphia chromosome, which then produces the Bcr-Abl fusion protein with aberrant kinase activity that promotes rapid cell proliferation. Imatinib mesylate binds up this crucial kinase, halting CML related growth. Imatinib mesylate has further been displayed to inhibit PDGFR and tyrosine kinases associated with c-Kit. Formulations containing Imatinib mesylate have been used in the treatment of various cancers. |
Specific Protocols | |